May 25, 2023 / 09:30PM GMT
Operator
Good afternoon, and welcome to Theseus Pharmaceuticals Investor Event. (Operator Instructions)
I would now like to turn the conference over to Brad Dahms, Chief Financial Officer at Theseus. Please proceed.
Bradford D. Dahms - Theseus Pharmaceuticals, Inc. - CFO
Thank you, operator, and good afternoon, everyone. Welcome to Theseus' investor event, where we will discuss initial dose escalation data from our Phase I/II clinical trial of THE-630 for patients with Advanced GIST. This afternoon, we issued a press release outlining these results. The press release and the presentation we will reference during today's event can be found on the Investors and Media section of Theseus's website at theseusrx.com. As a reminder, this call is being recorded and a replay will also be archived on the company's website for 90 days.
At this time, I would like to remind listeners that during this call, we may make forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties.
Theseus Pharmaceuticals Inc To Host Virtual Investor Event To Review Updated Data Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers